CD4 and neoplasm: Levy et al. demonstrated that the synergistic effect of TLR7/8 agonists with anti-OX40 antibodies was explained by the fact that TLR7/8 agonists such as R848 induce expression of the OX40 target on CD4 T cells in the tumor microenvironment (Fig. 8C) [335].